Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

autologous anti-Claudin18.2-transduced T lymphocytes CT041

A preparation of autologous T lymphocytes ex vivo transduced with a lentiviral vector encoding for a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-CLDN18.2CAR-transduced T lymphocytes specifically recognize and induce selective toxicity in CLDN18.2-expressing tumor cells. CLDN18.2, a tight junction protein, is expressed on a variety of tumor cells, but its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.
Synonym:autologous anti-Claudin18.2 CAR-T cells
autologous CAR-CLD18 T cells
autologous CAR-CLD18.2 T cells
Claudin18.2-redirected autologous cells
Claudin18.2-redirected autologous T cells
Code name:CT 041
CT-041
CT041
Search NCI's Drug Dictionary